eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development
New hire will accelerate commercial development of Company’s proprietary TriMix mRNA platform for oncology and infectious disease immunotherapies
Niel, Belgium, October xx, 2020 – eTheRNA immunotherapies NV (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, today announced that Michael Mulqueen has been appointed VP of Business Development. Following 15 years at F. Hoffman-La Roche in both scientific and management roles, Michael continued his successful career in business development with innovative companies such as Synosia and Silence Therapeutics.
“I am delighted to join eTheRNA at this exciting stage of its development when the Company is making major progress with the core oncology mRNA immunotherapy pipeline and accelerating the development of its infectious disease vaccine platform,“ said Mulqueen. “I have maintained a strong interest in vaccines and RNA, having originally been a virology team leader at Roche and more recently head of BD at Silence Therapeutics.”
CEO Steven Powell commented: “Michael will be a valuable addition to the team as we seek to leverage the potential of our TriMix platform both through our own pipeline development and through collaborations and partnerships.”
Information for editors
About eTheRNA immunotherapies
eTheRNA immunotherapies is a clinical-stage company developing innovative immunotherapies from its proprietary mRNA TriMix platform. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is developing products for the treatment of cancer and infectious disease.
Mobile +44 7711 821 527